本帖最后由 老马 于 2012-1-13 21:20 编辑
9 o6 y5 J" c5 _
8 G7 C5 M: E: y2 h- r6 u! x爱必妥和阿瓦斯丁的比较- O% i8 A" }$ X' u! `% |2 }5 x! p. o
1 {! e9 v( B0 y) `http://cancergrace.org/lung/2008/08/30/bms099-os-neg/
5 J8 h3 E. d/ @. y$ R- Q
+ ?! v$ q3 { I9 E
/ d, J' Z; j/ f7 r4 Ohttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/* S7 B2 M" ~0 r. W* s1 L) F: J+ q
==================================================
6 A# w8 f- F5 z/ L8 fOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
( ^0 F3 h! d) X4 R& ~Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.' g7 U) f# I) ?3 J% v
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.6 c( p: `: P9 I. W
|